Murphy-Benenato Kerry E, Olivier Nelson, Choy Allison, Ross Philip L, Miller Matthew D, Thresher Jason, Gao Ning, Hale Michael R
Department of Chemistry, Infection Innovative Medicines, and Discovery Sciences, AstraZeneca R&D, Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
ACS Med Chem Lett. 2014 Sep 23;5(11):1213-8. doi: 10.1021/ml500210x. eCollection 2014 Nov 13.
In the search for novel Gram-negative agents, we performed a comprehensive search of the AstraZeneca collection and identified a tetrahydropyran-based matrix metalloprotease (MMP) inhibitor that demonstrated nanomolar inhibition of UDP-3-O-(acyl)-N-acetylglucosamine deacetylase (LpxC). Crystallographic studies in Aquifex aeolicus LpxC indicated the tetrahydropyran engaged in the same hydrogen bonds and van der Waals interactions as other known inhibitors. Systematic optimization of three locales on the scaffold provided compounds with improved Gram-negative activity. However, the optimization of LpxC activity was not accompanied by reduced inhibition of MMPs. Comparison of the crystal structure of the native product, UDP-3-O-(acyl)-glucosamine, in Aquifex aeolicus to the structure of a tetrahydropyran-based inhibitor indicates pathways for future optimization.
在寻找新型革兰氏阴性菌药物的过程中,我们对阿斯利康的化合物库进行了全面搜索,鉴定出一种基于四氢吡喃的基质金属蛋白酶(MMP)抑制剂,该抑制剂对UDP-3-O-(酰基)-N-乙酰葡糖胺脱乙酰酶(LpxC)具有纳摩尔级别的抑制作用。嗜热栖热菌LpxC的晶体学研究表明,四氢吡喃与其他已知抑制剂形成相同的氢键和范德华相互作用。对该骨架上三个位点进行系统优化,得到了革兰氏阴性菌活性增强的化合物。然而,LpxC活性的优化并未伴随着对MMPs抑制作用的降低。将嗜热栖热菌中天然产物UDP-3-O-(酰基)-葡糖胺的晶体结构与基于四氢吡喃的抑制剂结构进行比较,为未来的优化指明了方向。